Received $20.0 million in February 2026 from Newsoara under an amended licensing agreementExpect to complete enrollment in the CATT1 Phase 3 ...

vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv ...

SCHB covers the full U.S. stock market with a tech tilt, while VTV focuses on large-cap value stocks led by financials and healthcare. VTV yields more than SCHB’s payout. VTV’s max drawdown has been ...

VTv Therapeutics Inc. (VTVT) on Tuesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 58 cents. The ...

VTVT stock outlook: underfollowed T1D catalyst with Phase 3 CATT1 cadisegliatin data due 2H2026, improved timeline and runway—read more on VTVT here.

About four months into the job, Deepa Prasad is resigning from the top perch at vTv Therapeutics after restructuring the company to focus on a late-stage Type 1 diabetes med and laying off a majority ...

VTV needs little introduction. It's Vanguard's leading large-cap value ETF with over $100 billion in assets under management and an ultra-low 0.04% expense ratio. VTV has struggled this year, lagging ...

Vanguard Value ETF carries a higher yield but slightly higher expenses than SPTM. SPTM has delivered stronger 1-year and 5-year growth, but with higher volatility and drawdowns. VTV tilts toward ...

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance ...